MinervaX announces completion of 47.4 mEUR financing with Sanofi Ventures, Wellington Partners, Adjuvant Capital and Industrifonden joining existing investors Novo Holding's REPAIR Impact Fund, Sunstone Life Science Ventures and LF Investment. Proceeds will be used to advance the Company's GBS vaccine through Phase II and preparation for Phase III. Minervax ApS is a biotechnology company based out of 28 Vedbendvej, Hellerup, C...
MinervaX announces completion of 47.4 mEUR financing with Sanofi Ventures, Wellington Partners, Adjuvant Capital and Industrifonden joining existing investors Novo Holding's REPAIR Impact Fund, Sunstone Life Science Ventures and LF Investment. Proceeds will be used to advance the Company's GBS vaccine through Phase II and preparation for Phase III. Minervax ApS is a biotechnology company based out of 28 Vedbendvej, Hellerup, Capital Region of Denmark, Denmark. MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci.The National Institute of Health of the US has identified prevention of GBS in newborns.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.